retatrutide gip glp-1 glucagon receptor agonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data The TRIUMPH-1 Phase 3 results

The semaglutide versus tirzepatide comparison provides foundational context for understanding how dual agonism differs from single agonism, which then extends to understanding how triple agonism differs from dual

If more than 12 hours have passed, skip it and continue with your regular schedule the next day

IVY RX is a telehealth platform

Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes

By Distribution Channel By distribution channel, drug stores & retail pharmacies accounted for a share of 44.68% in 2025 due to widespread geographic accessibility, established prescription dispensing networks, and pharmacist-led patient counseling that supports chronic therapy continuation

Oral GLP-1s dosing Oral GLP-1s are available in different dosage strengths